Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors

JAMA Netw Open. 2021 May 3;4(5):e217728. doi: 10.1001/jamanetworkopen.2021.7728.

Abstract

This cohort study examines the association of BRCA1 and BRCA2 with tumor mutation burden and response to immune checkpoint inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • BRCA1 Protein / genetics*
  • BRCA2 Protein / genetics*
  • Biomarkers, Tumor / genetics
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / mortality
  • Cohort Studies
  • Female
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use*
  • Kaplan-Meier Estimate
  • Mutation
  • Tumor Burden

Substances

  • BRCA1 Protein
  • BRCA1 protein, human
  • BRCA2 Protein
  • BRCA2 protein, human
  • Biomarkers, Tumor
  • Immune Checkpoint Inhibitors